BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1677038)

  • 1. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
    Grenader A; Healy DP
    J Pharmacol Exp Ther; 1991 Jul; 258(1):193-8. PubMed ID: 1677038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam.
    Hedge SS; Ricci A; Amenta F; Lokhandwala MF
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1237-45. PubMed ID: 2574743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam.
    Christie MI; Smith GW
    J Pharmacol Exp Ther; 1994 Feb; 268(2):565-70. PubMed ID: 7906731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog.
    Clark KL; Hilditch A; Robertson MJ; Drew GM
    J Hypertens; 1991 Dec; 9(12):1143-50. PubMed ID: 1685741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DA1 dopamine receptors in renal cortical collecting duct.
    Ohbu K; Felder RA
    Am J Physiol; 1991 Nov; 261(5 Pt 2):F890-5. PubMed ID: 1683170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats.
    Chen CJ; Apparsundaram S; Lokhandwala MF
    J Pharmacol Exp Ther; 1991 Feb; 256(2):486-91. PubMed ID: 1671595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally formed dopamine stimulates cAMP accumulation in LLC-PK1 cells via a DA1 dopamine receptor.
    Grenader A; Healy DP
    Am J Physiol; 1991 Jun; 260(6 Pt 2):F906-12. PubMed ID: 1647691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat.
    Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dopamine receptor agonists on the cAMP content in arteries of the rabbit.
    Zhu L; Zhao RR; Zhang WF
    Sheng Li Xue Bao; 2000 Jun; 52(3):247-51. PubMed ID: 11956574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A68930 is a potent, full agonist at dopamine1 (D1) receptors in renal epithelial LLC-PK1 cells.
    Grenader A; Healy DP
    Br J Pharmacol; 1992 Jun; 106(2):229-30. PubMed ID: 1356555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
    Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
    J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
    Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J
    J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study.
    Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D
    Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of fenoldopam.
    Nichols AJ; Ruffolo RR; Brooks DP
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):116S-119S. PubMed ID: 1974439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from distal nephron.
    Takemoto F; Cohen HT; Satoh T; Katz AI
    Pflugers Arch; 1992 Jul; 421(4):302-6. PubMed ID: 1357625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine stimulation of cAMP production in cultured opossum kidney cells.
    Cheng L; Precht P; Frank D; Liang CT
    Am J Physiol; 1990 Apr; 258(4 Pt 2):F877-82. PubMed ID: 1691897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human vasodilator responses to a dopamine agonist: possible mechanisms.
    Redman D; Thom SA; Hughes AD; Hasan S; Sever PS
    J Hypertens Suppl; 1985 Dec; 3(3):S177-8. PubMed ID: 2908815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic and pulmonary vascular effects of selective dopamine receptor blockade and stimulation in lambs.
    Polak MJ; Drummond WH
    Pediatr Res; 1993 Feb; 33(2):181-4. PubMed ID: 8094550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cloned human dopamine D1 receptor-mediated calcium release in 293 cells.
    Lin CW; Miller TR; Witte DG; Bianchi BR; Stashko M; Manelli AM; Frail DE
    Mol Pharmacol; 1995 Jan; 47(1):131-9. PubMed ID: 7838121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
    Zhao RR; Wang PH; Zhang WF; Fennell WH
    Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.